Antivirals Drug: Global Strategic Business Report

Global Antivirals Drug Market to Reach $145.3 Billion by 2030

The global market for Antivirals Drug estimated at US$104.2 Billion in the year 2022, is projected to reach a revised size of US$145.3 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2022-2030. DNA Polymerase Inhibitors, one of the segments analyzed in the report, is projected to record a 3.7% CAGR and reach US$14.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Reverse Transcriptase Inhibitors segment is readjusted to a revised 4.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $28.4 Billion, While China is Forecast to Grow at 6.9% CAGR

The Antivirals Drug market in the U.S. is estimated at US$28.4 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$29.9 Billion by the year 2030 trailing a CAGR of 6.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.2% and 3.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$19.5 Billion by the year 2030.

Select Competitors (Total 23 Featured) -

• AbbVie, Inc.
• Aurobindo Pharma Ltd.
• Bristol-Myers Squibb Company
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• F. Hoffmann-La Roche AG
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Mylan NV

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year